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Natural cell-mediated cytotoxicity was studied in 24 
patients with cutaneous T -cell lymphomas and in 18 age-
and sex-matched controls studied concomitantly. Per-
cent cytotoxicity was determined by 4-h 5 1Cr release 
assay using K562 targets at effector to target ratios of 
100:1, 50:1, and 25:1. Mean percent cytotoxicity was 
significantly lower in patients than in controls at an 
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Abbreviations: 
ADCC: antibody-dependent cellular cytotoxicity 
CTCL: cutaneous T-celllymphoma(s) 
MEM: minimum essential medium 
MEM-FCS: MEM with fetal calf serum 
NCMC: natural cell-mediated cytotoxicity 
NK: natural killer 
TNM: tumor size, node, metastasis 
effector to target cell ratio of 100:1. Likewise, decreased 
cytotoxicity was found at effector to target ratios of 50:1 
and 25:1, although this difference was not significant. 
When natural killer activity was analyzed separately for 
males and females, cytotoxicity was lower in both, al-
though the decrease was significant only for male pa-
tients. Impairment of natural killer activity ~d not cor-
relate with blood zinc levels, but appeared to correlate 
with stage of disease. 
Immune disturbances have been associated with cutaneous 
T-cell lymphomas (CTCL). Several studies have reported al-
terations in cellular [1-5] and humoral [6-8] immunity, al-
though some of the data are inconclusive. Recently, cells me-
diating antibody-dependent cellular cytotoxicity (ADCC) and 
natural killer (NK) cells have been gaining attention because of 
their role in natural host defense mechanisms. Investigation of 
ADCC in patients with CTCL showed that ADCC was de-
creased in Sezary syndrome, but normal in mycosis fungoides, 
suggesting impairment may correlate with severity of disease 
[9]. In the present study we determined NK activity in patients 
Aug. 1983 
with various stages of CTCL and compared this to age- and 
sex-matched controls tested concomitantly. Since zinc defi-
ciency has been found in various malignancies [10], and may 
result in reduced NK activity [11], we also analyzed blood zinc 
and copper levels at the time of study. 
MATERIALS AND METHODS 
Patients and Controls 
Twenty-fow· patients (16 males and eight females) with histologically 
confirmed CTCL were studied. Patients ranged in age from 30 to 78 
years (mean, 59.9) and duration of disease !'rom time of diagnosis ranged 
from 1 week to 13 years (mean, 3 years). E leven patients had received 
no therapy for at least 1 month prior to study, 3 of whom had never 
been treated; 10 were receiving local therapy (topical mechlorethamine 
hydrochloride, ultraviolet A radiation, or electron beam therapy) and 
3 were on both local therapy and systemic chemotherapy. Using the 
TNM (tumor size, node, metastasis) classification, 3 patients had Stage 
Ia disease and 3 had Ib; 7 patients had Stage Ila and 3 had lib; 6 
patients had Stage IVa and 1 had IVb. Control subjects (12 males and 
6 females) consisted of 18 normal volunteers aged 39-88 (mean, 58.3). 
After obtaining informed consent, all blood samples were drawn be-
tween 9:00-10:00 AM. 
Total Lymphocyte Count 
This was derived from the total leukocyte count and differential 
white blood cell count on Wright's stained peripheral blood smears. 
Isolation of Peripheral Blood Lymphocytes 
Heparinized venous blood was mixed with phosphate-buffered saline 
and layered on a Ficoll-Hypaque gradient. After 30 min of centrifuga-
tion at 400 g, interface cells were collected, washed with Eagle's 
minimum essential medium (MEM), and resuspended in MEM supple-
mented with 10% fetal calf serum, 200 mM glu tamine, 100 JlU/ ml 
penicillin, and 100 jlg/ml streptomycin (MEM-FCS). In the resultant 
preparations, cell viability was greater than 95% by trypan blue dye 
exclusion. 
Natural Cell·Mediated Cytotoxicity (NCMC) 
Target cells were K562 cells, standard targets for NK activity, which 
were kindly supplied by Dr. PaulL. Black (Department of Microbiology 
and Immunology, Temple University Health Sciences Center, Phila-
delphia, Pennsylvania) . These cells were carried in vitro in MEM 
supplemented with 5% fetal calf serum and 200 mM glu tamine. K562 
cells (5 X 106 ) were labeled by incubation in 0.05 mCi sodium 5 1Cr-
chromate (1 mCi/ml) for 1 h at 37°C, washed 3 times in MEM-FCS, 
and resuspended at 105 cells/ mi. 
Peripheral blood lymphocytes (100 Jll) were added to 100 Ill of target 
cells in 96-well V-bottom microtiter plates (Linbro Chemicals, New 
Haven, Connecticut ) at varying concentrations to give effector to target 
cell ratios of 100:1, 50:1, and 25:1. All samples were run in triplicate. 
The cells were centrifuged at 40 g for 2 min, incubated at 37°C in a 
humidified atmosphere containing 5% C02-95% air for 4 h, then centri-
fuged at 200 g for 10 min. Supernatant (100 jli) from each well was 
aspirated, and experimental 51 Cr release determined in a Searle gamma 
scintillation counter. Spontaneous release was assessed by incubating 
"'Cr-labeled K562 cells in media without effector cells, and in all 
experiments was below 10%. Total "'Cr incorporated was determined in 
100 Jll of 6 1Cr-labeled K562 cells and divided by 2. Percent cytotoxicity 
was calculated as fo llows: 
Mean experimental release 
- mean spontaneous release 
-----------X 100 
Mean total incorporated 
- mean spontaneous release 
Blood Zinc and Copp er Levels 
Blood metal levels were analyzed by anodic stripping voltammetry 
(ESA 2011/ PMI1014S voltammeter) . Refrigerated 100-JLI blood samples 
from capillary containers were placed in trace metal-fTee analysis cells, 
combined with 2 rinses of 50-Jll aliquots of distilled deionized water and 
digested to dry white residue at 200°C in 300 Jll of acid reagent (24 
parts HNOa:24 parts HClO.:I part H 2S04 ). The acid-digested samples 
wer.e then reconstituted in trace metal-free buffer (1.0 formula weigh t 
sodium acetate-0.2 formula weight sodium chloride) and electroplated 
at -1170/mv for 25 min while nitrogen bubbled through the solu tions. 
The electrodes were subsequent ly stripped of zinc and copper while 
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recording amperometric peak heights. Metal contents were calculated 
from peak height values obtained from concurrently run standards with 
corresponding concentrations of elements expressed as Jlg/ 100 ml. 
RESULTS 
Total lymphocyte count was significantly lower in CTCL 
(1393 ± 101/mm3 ) (SEM) than in controls (2010 ± 164/ mm3 ) 
(p < .01). Mean percent NCMC in CTCL (47.6 ± 3.9%) was 
also significantly less t han controls (59.5 ± 3.4%) at an effector 
to target cell ratio of 100:1 (p < .05) (Fig 1). Likewise, decreased 
NK activity was present at effector to target cell ratios of 50:1 
(42.1 ± 3.9% VS 53.2 ± 3.7%) and 25:1 (30.8 ± 3.8% VS 38.8 ± 
3.5%), although this difference was not significant (Fig 1). 
Since NK activity has been reported to be higher in males 
than females [12], we analyzed our results for each sex sepa-
rately. Percent cytotoxicity was 46.5 ± 5.1% in males with 
CTCL compared to 62.3 ± 4.1% in male controls at an effector 
to target cell ratio of 100:1 (p < .05) (Fig 2). Similarly, decreased 
NCMC was present in males at effector to target cell ratios of 
50:1 (40.6 ± 5.1% vs 56.9 ± 3.9%) (p < .05) and 25:1 (29.2 ± 4.9% 
vs 41.7 ± 3.6%) (p < .10), respectively. The 6 male patients with 
values below the mean consisted of 4 patients with intracuta-
neous and 2 patients with extracutaneous disease. Four patients 
were on no systemic chemotherapy at the time of study, while 
2 had received their last dose of single agent chemotherapy 3 
weeks and 1 week prior to study, respectively. Absolute lym-
phocyte count was below control mean in 5 of the 6 patients, 
and at the mean in the 1 patient whose NCMC was closest to 
the mean. However, NK activity in females with CTCL (48.5 
± 6.2%), was only slightly lower than female controls (53.8 ± 
5.8%) at an effector to target cell ratio of 100:1 (Fig 2). This was 
apparent also at effector to target cell ratios of 50:1 (43.3 ± 6.1% 
vs 45.8 ± 7.5%) and 25:1 (31.7 ± 5.9% vs 33.1 ± 7.7%), respec-
tively. 
Since a correlation between severity of CTCL and immuno-
logic abnormalities has been reported [3-5,9], NK activity was 
also analyzed according to stage of CTCL. NK activity in 7 
patients with extracutaneous disease (39.9 ± 9.1%) was lower 
than in 17 patients with only intracutaneous involvement (50.2 
± 4.1%) at an effector to target cell ratio of 100:1, but this 
difference was not significant. Likewise, using either the TNM 
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FIG 1. Natural cell-mediated cytotoxicity in CTCL and in controls. 
Values plotted are mean± SE. Effector to target ratios are shown on 
















FIG 2. Natural cell-mediated cytotoxicity in CTCL (0 ) and in con-
trols (e) shown separately for males and females. NCMC was deter-
mined by 4 h 51Cr release assay using K562 targets at effector to target 
ratio of 100:1. Individual values and mean of each group are shown. * 
= p < .05. 
staging system for CTCL or classification into premycotic, 
plaque, tumor, or erythroderma stages, NK activity was always 
lower in advanced stages of CTCL, although again this decrease 
was not significant. 
No significant difference was observed in blood zinc levels in 
CTCL (51.4 ± 9.7 {lg/100 ml) and in controls (58.5 ± 10.5 {lg/ 
100 ml), or in blood Cu levels in CTCL (90.7 ± 3.3 {lg/100 ml) 
and in controls (91.4 ± 3.5 {lg/ 100 ml). Furthermore, there was 
no significant correlation between zinc levels and NCMC in 
CTCL (r = - .2) . 
DISCUSSION 
The results of our study show reduced NK activity in patients 
with CTCL. This is not explained by the decrease in total 
lymphocytes in CTCL, since the same ratio of lymphocytes to 
target cells is used in the NCMC assay. In addition, the impair-
ment in NK activity was not related to blood zinc levels. An 
attractive hypothesis might be that increased levels of thymic 
factor found in CTCL [13] depress NK activity, since in vitro 
treatment of lymphocytes with human thymosin lowered NK 
activity [12]. Alternatively, the decrease in NK activity might 
be related to treatment of CTCL. Radiation, cyclophosphamide, 
and steroids have all been associated with reduced NK activity 
[12]. Although NCMC in 13 patients who were receiving either 
local or systemic therapy at the time of study was lower than 
in 11 patients who had received no treatment for at least 1 
month prior to study, the difference was not significant. How-
ever, whether impairment of NK activity .is secondary to de-
creased numbers of NK cells or reduced function was not 
assessed in this study. It is also possible that antibodies against 
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NK cells may be present in the sera of patients with CTCL, 
similar to systemic lupus erythematosus [14]. 
When NK activity was analyzed separately for males and 
females, the reduction in NCMC in male patients compared to 
male controls was significant, whereas for females the decrease 
in NCMC was not significant. It is possible that this apparent 
difference is related to the smaller number of females studied. 
However, it could be postulated that CTCL occurs more com-
monly in males than in females because of impairment of NK 
activity. 
The depression of NK activity seen in CTCL appears to be 
greater in more advanced stages of CTCL. Similarly, defective 
cell-mediated immunity [3-5] and ADCC [9] were found to 
correlate with stage of disease. 
Our findings are consistent with a recent letter to the editor, 
reporting decreased NK activity in 10 patients with CTCL 
[15]. In addition, NK activity was found to be significantly 
decreased in 59 untreated patients with malignant lymphoma 
(27.5% ± 19.1%) when compared to healthy controls (43.7 ± 
17.3%) and patients with nonlymphoid tumors (46.3 ± 16.9%) 
[16]. Although the physiologic significance of this impairment 
is uncertain, it is possible that decreased NK activity may 
contribute to the development of lymphomas, including CTCL. 
Further studies of the mechanisms responsible for this altera-
tion of NK activity in CTCL are indicated. 
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